J&J Pours $785 Million Into an Unproven Cancer-Tech Bet

Johnson & Johnson will pay $785 million — including $465 million for an ownership stake — to work with Sail Biomedicines on a new type of cancer treatment that reprograms immune cells inside the body. No treatment of this kind has yet produced proven results in published research. The deal rests entirely on early lab-stage findings.